Abstract
Hepatitis C is a current pandemic liver disease caused by the hepatitis C virus (HCV) with high morbidity and mortality. Recently, the direct-acting antiviral agents (DAAs) targeting HCV NS3/4A, NS5A and NS5B have become the most effective therapies against HCV infection in the clinical treatment. Among them, the second-generation of NS3/4A inhibitors have emerged as the mainstay of the DAA therapies, which are derived from the peptide substrate of NS3/4A protease and modified with various tailor-made amino acids in order to achieve high sustained virologic response (SVR) against HCV. This review summarizes sixteen examples of the second-generation of HCV NS3/4A inhibitors, mainly focusing on the clinical application, structure development, structure-activity relationship (SAR) and their synthesis.
Keywords: Hepatitis C virus (HCV), pandemic, direct-acting antiviral agents (DAAs), NS3/4A protease inhibitor, tailor-made amino acids, structure-activity relationship (SAR), asymmetric synthesis, ring-closing metathesis (RCM).
Current Pharmaceutical Design
Title:The Second-generation of Highly Potent Hepatitis C Virus (HCV) NS3/4A Protease Inhibitors: Evolutionary Design Based on Tailor-made Amino Acids, Synthesis and Major Features of Bio-activity
Volume: 23 Issue: 30
Author(s): Shuni Wang, Yibing Wang, Jiang Wang, Tatsunori Sato, Kunisuke Izawa*, Vadim A. Soloshonok*Hong Liu*
Affiliation:
- Hamari Chemicals Ltd., 1-4-29 Kunijima, Higashi-Yodogawa-ku, Osaka 533-0024,Japan
- IKERBASQUE, Basque Foundation for Science, Alameda Urquijo 36-5, Plaza Bizkaia, 48011 Bilbao,Spain
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203,China
Keywords: Hepatitis C virus (HCV), pandemic, direct-acting antiviral agents (DAAs), NS3/4A protease inhibitor, tailor-made amino acids, structure-activity relationship (SAR), asymmetric synthesis, ring-closing metathesis (RCM).
Abstract: Hepatitis C is a current pandemic liver disease caused by the hepatitis C virus (HCV) with high morbidity and mortality. Recently, the direct-acting antiviral agents (DAAs) targeting HCV NS3/4A, NS5A and NS5B have become the most effective therapies against HCV infection in the clinical treatment. Among them, the second-generation of NS3/4A inhibitors have emerged as the mainstay of the DAA therapies, which are derived from the peptide substrate of NS3/4A protease and modified with various tailor-made amino acids in order to achieve high sustained virologic response (SVR) against HCV. This review summarizes sixteen examples of the second-generation of HCV NS3/4A inhibitors, mainly focusing on the clinical application, structure development, structure-activity relationship (SAR) and their synthesis.
Export Options
About this article
Cite this article as:
Wang Shuni , Wang Yibing, Wang Jiang, Sato Tatsunori, Izawa Kunisuke *, Soloshonok A. Vadim*, Liu Hong*, The Second-generation of Highly Potent Hepatitis C Virus (HCV) NS3/4A Protease Inhibitors: Evolutionary Design Based on Tailor-made Amino Acids, Synthesis and Major Features of Bio-activity, Current Pharmaceutical Design 2017; 23 (30) . https://dx.doi.org/10.2174/1381612823666170522122424
DOI https://dx.doi.org/10.2174/1381612823666170522122424 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Functions of Fukutin, a Gene Responsible for Fukuyama Type Congenital Muscular Dystrophy, in Neuromuscular System and Other Somatic Organs
Central Nervous System Agents in Medicinal Chemistry Diagnostic and Therapeutic Uses of Nanomaterials in the Brain
Current Medicinal Chemistry Recent Design and Structure-Activity Relationship Studies on the Modifications of DHFR Inhibitors as Anticancer Agents
Current Medicinal Chemistry New Developments in the Discovery of Agents to Treat Hepatitis C
Current Topics in Medicinal Chemistry Parallel Synthesis of a Biased Library of Thiazolidinones as Novel Sodium Channel Antagonists
Combinatorial Chemistry & High Throughput Screening Drug Discovery and Design for Complex Diseases through QSAR Computational Methods
Current Pharmaceutical Design Molecular Determinants of Selective Agonist and Antagonist Binding to the Histamine H4 Receptor
Current Topics in Medicinal Chemistry Privileged Structures: Applications in Drug Discovery
Combinatorial Chemistry & High Throughput Screening Utility of Walk Tests in the Progression of Mild COVID-19 Infection at a Tertiary Hospital in North India
Recent Advances in Anti-Infective Drug Discovery COVID-19 Severity: Lung-Heart Interplay
Current Cardiology Reviews Behavioral Tasks Evaluating Schizophrenia-like Symptoms in Animal Models: A Recent Update
Current Neuropharmacology A Framework for Direct Locating and Conformational Sampling of Protein Structural Motifs
Protein & Peptide Letters CD47 Functionalization of Nanoparticles as a Poly(ethylene glycol) Alternative: A Novel Approach to Improve Drug Delivery
Current Drug Targets Nef Surfaces: Where to Interfere with Function
Current HIV Research A Review on Structures and Functions of Bcl-2 Family Proteins from Homo sapiens
Protein & Peptide Letters Combination of Hydroxychloroquine, Melatonin and Mercaptopurine as a Possible Intervention for Prophylaxis and Treatment of Novel COVID-19 Infection
Coronaviruses Transcranial Brain Stimulation in Schizophrenia: Targeting Cortical Excitability, Connectivity and Plasticity
Current Medicinal Chemistry Quantitative Structure Activity Relationship (QSAR) Analysis of Substituted 4-Oxothiazolidines and 5-Arylidines as Lipoxygenase Inhibitors
Mini-Reviews in Medicinal Chemistry Sigma Receptors and Cocaine Abuse
Current Topics in Medicinal Chemistry The Chronicle of COVID-19 and Possible Strategies to Curb the Pandemic
Current Medicinal Chemistry